Here's Why Neoleukin Therapeutics Dropped Today
The development-stage drug company announced the pricing of a public offering of common stock.
Is Aerie Pharmaceuticals a Buy?
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Is Iovance Biotherapeutics a Buy?
After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.
Here's Why BioNTech Jumped Today
The German biopharma announced a $250 million private investment.
Here's Why Athersys Stock Is Soaring Today
The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.
Is Wall Street Wrong About Mesoblast?
The cell therapy developer expects to have clinical data for its COVID-19 treatment soon. Will it deliver a historic success or continue the poor track record of stem cell candidates?
Shares of Renewable Energy Group Slide After Revising Q2 Outlook Lower
The biomass-based diesel leader is suffering from both poor market conditions and embarrassing errors in its previous guidance.
Here's Why Agenus Stock Jumped Higher Today
The development-stage biopharma delivered two encouraging updates.
Silver Stocks Jump as Confirmed COVID-19 Cases Rise
Investors are betting precious metals will prove resilient through the ongoing economic slowdown.
Invitae Surges on $1.4B Acquisition of ArcherDX
The genetic testing company pulled the trigger on its largest acquisition yet.
Here's Why Selecta Biosciences Stock Is Soaring Today
A bullish article is sending shares higher.
Here's Why IDEAYA Biosciences Lost Nearly 23% Today
The development-stage drug developer is selling common stock to raise cash. It's a wise move.
Here's Why PolyMet Mining Is Soaring This Week
The development-stage mining company is one step closer to starting operations at a long-delayed project in Minnesota.
Here's Why Selecta Biosciences Is Tumbling Today
A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.
2 Top Small-Cap Stocks to Buy Right Now
Volatile stock market or not, these two drug developers are well positioned for long-term success.
Here's Why Alliance Resource Partners Fell as Much as 13.5% Today
The Fed thinks the economy will take more time to recover than Wall Street was expecting, which is bad news for this coal stock.
Here's Why Invitae Fell as Much as 10.1% Today
The growth stock is an easy target in a volatile market.
Here's Why Renewable Energy Group Dropped Over 10% Today
The small-cap stock hit an all-time high earlier this month, but gloomy economic outlooks have investors rethinking the company's valuation.
New Gold Rises as Much as 12.9% on Series of Financing Deals
The gold miner is making moves to improve its near-term financial flexibility.
Here's Why Albemarle Gained 24.6% in May
The world's leading lithium producer benefitted from rising confidence about the pace of a possible economic recovery.